Mallinckrodt PLC (NYSE:MNK) was down 7.2% during trading on Friday . The stock traded as low as $22.08 and last traded at $22.09. Approximately 1,332,255 shares traded hands during trading, a decline of 28% from the average daily volume of 1,851,446 shares. The stock had previously closed at $23.80.

Several equities research analysts recently commented on MNK shares. Canaccord Genuity set a $40.00 target price on Mallinckrodt and gave the company a “buy” rating in a report on Sunday, November 25th. B. Riley lowered their price objective on Mallinckrodt to $21.00 and set a “neutral” rating for the company in a research note on Monday, December 31st. Mizuho restated a “neutral” rating on shares of Mallinckrodt in a research note on Monday, December 17th. Piper Jaffray Companies set a $39.00 price objective on Mallinckrodt and gave the company a “buy” rating in a research note on Friday, December 7th. Finally, Wells Fargo & Co set a $27.00 price objective on Mallinckrodt and gave the company a “hold” rating in a research note on Friday, December 7th. Four research analysts have rated the stock with a sell rating, nine have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $30.88.

The company has a quick ratio of 1.17, a current ratio of 1.51 and a debt-to-equity ratio of 2.10. The firm has a market capitalization of $1.84 billion, a PE ratio of 2.76, a price-to-earnings-growth ratio of 0.22 and a beta of 2.31.

Mallinckrodt (NYSE:MNK) last issued its earnings results on Tuesday, February 26th. The company reported $2.18 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.20. The business had revenue of $834.90 million for the quarter, compared to analysts’ expectations of $681.45 million. Mallinckrodt had a positive return on equity of 11.14% and a negative net margin of 134.63%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm posted $2.01 EPS. Research analysts forecast that Mallinckrodt PLC will post 8.21 EPS for the current year.

Several hedge funds have recently modified their holdings of MNK. Oregon Public Employees Retirement Fund grew its stake in Mallinckrodt by 1,480.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 520,326 shares of the company’s stock valued at $33,000 after purchasing an additional 487,394 shares in the last quarter. FNY Investment Advisers LLC lifted its position in shares of Mallinckrodt by 210.4% in the fourth quarter. FNY Investment Advisers LLC now owns 2,288 shares of the company’s stock worth $36,000 after buying an additional 1,551 shares during the last quarter. We Are One Seven LLC acquired a new stake in shares of Mallinckrodt in the fourth quarter worth about $38,000. QS Investors LLC lifted its position in shares of Mallinckrodt by 14.3% in the fourth quarter. QS Investors LLC now owns 4,000 shares of the company’s stock worth $64,000 after buying an additional 500 shares during the last quarter. Finally, Quantamental Technologies LLC acquired a new stake in shares of Mallinckrodt in the fourth quarter worth about $80,000.

COPYRIGHT VIOLATION WARNING: “Mallinckrodt (MNK) Trading Down 7.2%” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2019/03/24/mallinckrodt-mnk-trading-down-7-2.html.

Mallinckrodt Company Profile (NYSE:MNK)

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Featured Story: What are earnings reports?

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.